Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
HERTFORDSHIRE, England and PITTSBURGH , and NEWARK, Calif. , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX
View HTML
Toggle Summary Mylan to Present at Raymond James 39th Annual Institutional Investors Conference
HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced that its CFO, Ken Parks , will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Fla. , on Monday, Mar. 5, 2018 , at 1:40 p.m. ET .
View HTML
Toggle Summary Mylan to Present at Barclays Global Healthcare Conference
HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced that its CEO, Heather Bresch , will present at the Barclays Global Healthcare Conference in Miami Beach, Fla. , on Wednesday, Mar. 14, 2018 , at 3:20 p.m. ET .
View HTML
Toggle Summary Mylan Defeats Allergan's Maneuver to Rent Tribal Sovereign Immunity to Avoid Restasis® Patent Challenge
U.S. Patent Trial and Appeal Board denies St. Regis Mohawk Tribe's motion to terminate Restasis patent challenge Decision finds that Tribal sovereign immunity does not apply to inter partes review proceedings Federal District Court previously held patents invalid HERTFORDSHIRE, England
View HTML
Toggle Summary 16-Year Veteran Director Wendy Cameron to Retire from Mylan N.V. Board after 2018 AGM
Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors HERTFORDSHIRE, England and PITTSBURGH , Feb. 26, 2018 /PRNewswire/ -- The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced that non-executive Director Wendy Cameron will retire from the Board after more
View HTML
Toggle Summary Mylan Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
- DTG/FTC/TAF is comprised of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg - - Mylan's DTG/FTC/TAF will be the first TAF-based fixed-dose combination to be offered to patients in developing countries being treated for HIV - HERTFORDSHIRE, England
View HTML
Toggle Summary Mylan to Release 2017 Fourth Quarter and Full Year Results and 2018 Guidance on Feb. 28, 2018
HERTFORDSHIRE, England , and PITTSBURGH , Feb. 8, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and full year 2017 financial results, as well as its 2018 financial guidance, on Wednesday, Feb. 28 , following the close of the U.S.
View HTML
Toggle Summary Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets
- Launch further strengthens Mylan's leading antiretroviral portfolio -- Mylan is eligible for 180 days of exclusivity -
View HTML
Toggle Summary Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
FDA Assigns PDUFA Target Action Date of November 13, 2018
View HTML
Toggle Summary Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine
First biosimilar from Mylan and Biocon's joint portfolio recommended for approval in the European Union (EU)
View HTML